| Literature DB >> 27258533 |
Michael Inskip1, Yorgi Mavros1, Perminder S Sachdev2,3, Maria A Fiatarone Singh1,4,5,6.
Abstract
BACKGROUND: Individuals with Lewy body Dementia (LBD), which encompasses both Parkinson disease dementia (PDD) and Dementia with Lewy Bodies (DLB) experience functional decline through Parkinsonism and sedentariness exacerbated by motor, psychiatric and cognitive symptoms. Exercise may improve functional outcomes in Parkinson's disease (PD), and Alzheimer's disease (AD). However, the multi-domain nature of the LBD cluster of symptoms (physical, cognitive, psychiatric, autonomic) results in vulnerable individuals often being excluded from exercise studies evaluating physical function in PD or cognitive function in dementia to avoid confounding results. This review evaluated existing literature reporting the effects of exercise interventions or physical activity (PA) exposure on cluster symptoms in LBD.Entities:
Mesh:
Year: 2016 PMID: 27258533 PMCID: PMC4892610 DOI: 10.1371/journal.pone.0156520
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PRISMA flow chart of search.
PEDro score: Experimental studies.
| Criteria | Study | |
|---|---|---|
| Telenius et al 2015 | Rochester et al. 2009 | |
| 1. Eligibility criteria were specified | YES | YES |
| 2. Subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which treatments were received) | YES | NO |
| 3. Allocation was concealed | YES | NO |
| 4. The groups were similar at baseline regarding the most important prognostic indicators | NO | NO |
| 5. There was blinding of all subjects | NO | NO |
| 6. There was blinding of all therapists who administered the therapy | NO | NO |
| 7. There was blinding of all assessors who measured at least one key outcome | YES | NO |
| 8. Measures of at least one key outcome were obtained from more than 85% of the subjects initially allocated to groups | YES | YES |
| 9. All subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analysed by “intention to treat” | YES | YES |
| 10. The results of between-group statistical comparisons are reported for at least one key outcome | NO | NO |
| 11. The study provides both point measures and measures of variability for at least one key outcome | NO | NO |
| 12. Exercise intervention was supervised | Yes | Yes |
CARE Criteria: Case report studies.
| Criteria | Study | |||
|---|---|---|---|---|
| Ciro et al. 2013 | Tabak et al 2013 | Dawley 2014 | ||
| Title | 1. The words ‘‘case report’ should appear in the title along with the area of focus | N | Y | Y |
| Key words | 2. 2 to 5 key words that identify areas covered in this case report | Y | Y | N |
| Abstract | 3a. Introduction—what is unique about this case? What does it add to the literature | Y | Y | Y |
| 3b. The main symptoms of the patient and important clinical findings | N | Y | Y | |
| 3c. The main diagnosis, therapeutic interventions and outcomes | Y | Y | Y | |
| 3d. Conclusion—what are the main ‘take-away’ lessons from this case | Y | Y | Y | |
| Introduction | 4. One or two paragraphs summarizing why this case is unique with references | Y | Y | Y |
| Patient information | 5a. De-identified demographic information and other patient specific information | Y | Y | Y |
| 5b. Main concerns and symptoms of the patients | Y | Y | Y | |
| 5c. Medical, family and psychosocial history including relevant genetic information | Y | Y | Y | |
| 5d. Relevant past interventions and their outcomes | Y | Y | Y | |
| Clinical findings | 6. Describe the relevant physical examination and other significant clinical findings | Y | Y | Y |
| Timeline | 7. Important information from the patient’s history organized as a timeline | N | N | N |
| Diagnostic | 8a. Diagnostic methods (such as PE, Laboratory testing, imaging, surveyed | Y | Y | Y |
| Assessment | 8b. Diagnostic challenges (such as access, financial, or cultural) | N | N | Y |
| 8c. Diagnostic reasoning including other diagnosis considered | N | N | Y | |
| 8d. Prognostic characteristics (such as staging in oncology) where applicable | N | N | N | |
| Therapeutic intervention | 9a. Types of intervention (such as pharmacologic, surgical, preventive, self-care) | Y | Y | Y |
| 9b. Administration of intervention (such as dosage, strength, duration) | Y | Y | Y | |
| 9c. Changes in intervention (with rationale) | Y | Y | Y | |
| Follow-up and outcome | 10a. Clinician and patient assessed outcomes (when appropriate) | Y | Y | Y |
| 10b. Important follow up diagnostic and other results | Y | Y | Y | |
| 10c. Intervention adherence and tolerability (how was this assessed) | Y | Y | Y | |
| 10d. Adverse and unanticipated events | Y | N | Y | |
| Discussion | 11a. Discussion of the strengths and limitations in your approach to this case | Y | Y | Y |
| 11b. Discussion of the relevant medical literature | Y | Y | Y | |
| 11c. The rationale for conclusions (including assessment of possible causes) | Y | Y | Y | |
| 11d. The primary ‘take-away’ lessons of this case report | Y | Y | Y | |
| Patient perspectives | 12. When appropriate the patients share their perspective on the treatments they received | N | N | N |
| Informed consent | 13. Did the patient give informed consent? Please provide if requested | Y | Y | Y |
Cohort Characteristics.
Data reported in brackets as mean standard deviation (SD) or as individual values where appropriate. NR—Not reported, PDD—Parkinson’s disease dementia, DLB—dementia with Lewy bodies, MMSE—Mini-mental State Exam score; ranges from 0—30 with higher scores indicative of better cognitive function, UPDRS—unified Parkinson’s disease rating scale (part I—mentation, II—Activities of daily living, III—motor).
| Citation | Number of participants | Average Age in years | Sex | Diagnosis | Time since diagnosis in years | MMSE /Cog scores | UPDRS | Hahn’s and Yohr stage | Co-morbid diseases/ conditions | Neuro-psychological medications | Weight/BMI | Residential Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rochester et al. 2009 | 9 | 75 (6) | M | PDD/PD-MCI | 6 (6) | 22(3) | Part-III, 44(35.5–47.0) | 3 (2.5–3.0) | NR | NR | NR | Community |
| Ciro et al. 2013 | 1 | 73 | F | DLB | 2 | 12 | NR | 4 | Low back pain, hip arthritis, osteoporosis, heart palpitations | Rivastigmine, Citalopram, Rasagiline | NR | Community |
| Tabak et al 2013 | 1 | 61 | M | PDD | 0 | 17 [MoCA | Part-I 11/16, Part-II 15/52 | NR | Deep brain stimulation, total knee replacement | Cardidopa- Levodopa | NR | Community |
| Dawley, 2014 | 1 | 57 | M | DLB | 1 | NR | NR | NR | None | Cardidopa /Levodopa, anti-depressant and anti-hallucinogenic medication | NR | Community |
| Telenius et al 2015 | 4 | 84 (10) | 3F, 1M | PDD | NR | 16 (7.1) | NR | NR | Average = 2 co-morbid | Average daily medications = 6.5 | NR | Nursing home |
A 5 participants indicative of dementia, remaining 4 have MCI,
B Time since diagnosis for Parkinson’s disease only,
C participant reported memory concerns 2 years prior, but seemed to have been diagnosed with dementia in the study,
D MoCA = The Montreal Cognitive Assessment was used; score ranges from 0–30 with higher scores indicative of better cognition.
Performance based tests of function.
N/A = not applicable, NR = not reported.
| Study | Measure | EXERCISE | CONTROL | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Outcome | Baseline | Outcome | % change | ES (SD) | |||
| Ciro et al. 2013 (n = 1) | 1 | 5 | 400 | |||||
| 1 | 6 | 500 | ||||||
| 0 | ||||||||
| Dawley 2014 (n = 1) | 4 | 8 | 100 | |||||
| Telenius et al. 2015 (n = 4) | (#1) 6 | (#1) 8 | (#3) 7 | (#3) 8 | N/A | N/A | ||
| (#2) 5 | (#2) 8 | (#4) 4 | (#4) 4 | N/A | N/A | |||
| Rochester et al 2009 (n = 9) | 0.72 | 0.88 | 22.2 | |||||
| Tabak et al 2013 (n = 1) | 0.96 | 0.92 | -4.2 | |||||
| Dawley 2014 (n = 1) | 0.8 | 1.43 | 78.8 | |||||
| Telenius et al. 2015 (n = 4) | (#1) 0.35 | (#1) 0.3 | (#3) 0.59 | (#3) 0.49 | N/A | N/A | ||
| (#2) 0.41 | (#2) 0.71 | (#4) 0.36 | (#4) 0.34 | N/A | N/A | |||
| Telenius et al. 2015 (n = 4) | (#1) 0.49 | (#1) 0.5 | (#3) 0.93 | (#3) 1.11 | N/A | N/A | ||
| (#2) 1.1 | (#2) 1.54 | (#4) 0.71 | (#4) 0.57 | N/A | N/A | |||
| Rochester et al 2009 (n = 9) | 0.65 | 0.74 | 13.8 | |||||
| Tabak et al 2013 (n = 1) | 100.6 | 129.5 | 28.7 | |||||
| Dawley 2014 (n = 1) | 480.36 | 562.05 | 17.0 | |||||
| Tabak et al 2013 (n = 1) | 60.7 | 102.7 | 69.2 | |||||
| Tabak et al 2013 (n = 1) | 13 | 23 | ||||||
| Dawley 2014 (n = 1) | 21 | 25 | ||||||
| Telenius et al. 2015 (n = 4) | (#1) 23 | (#1) -27 | (#3) 42 | (#3)—41 | N/A | N/A | ||
| (#4) 29 | (#4)—30 | N/A | N/A | |||||
| Dawley 2014 (n = 1) | 15.45 | 9.05 | -41.4 | |||||
| Dawley 2014 (n = 1) | 67 | 40 | ||||||
| Tabak et al. 2013 (n = 1) | 83 | 70 | -15.7 | |||||
| 15 | 6 | - 60.0 | ||||||
| Telenius et al. 2015 (n = 4) | (#1) 11 | (#1) NR | (#3) 11 | (#3) 14 | N/A | N/A | ||
| (#2) 13 | (#2) 12 | (#4) 12 | (#4) 13 | N/A | N/A | |||
A Participant data presented individually (Participant #1–4),
B Unit changed from cm/s to m/s,
C Unit changed from mph to m/s and distance from feet to meters,
D Results rounded to nearest 2 decimal places,
AR -Assessor rated,
SR-Subject completed.
COPM—Canadian occupational performance measure. 10-point scale where a higher value indicates better performance/satisfaction, GAS—Goal Attainment scale is scored from -2, -1 (sub-optimal result), 0 (achieved goal), 1, 2 (achieved more than goal), MiniBESTest—Mini Balance evaluation systems test is scored out of 28, with higher scores indicating better function, UPDRS-II—Unified Parkinson’s disease rating scale subscale II (ADL)—is rated out of 52 with lower scores indicating less impairment, PDQ-39 —Parkinson’s disease Questionnaire -39 is rated out of 156 where a lower score indicates less impairment. Barthel Index—a rating scale out of 20, where a higher score indicates more functionality in Instrumented ADL, G—Code—a scale for reporting disability where a higher level of disability is reflected in a higher % range, Functional Gait Assessment—A scale out of 30, where a lower score indicates less function, Berg Balance scale—A scale out of 56 where a higher score indicates more function.
Intervention Characteristics. NR—Not reported.
| Citation | Exercise Modality | Frequency (sessions/wk.) | Session/ stimulus duration (minutes) | Program Duration (wk) | Volume (frequency x duration) minutes/wk. | Intensity target | Progression |
|---|---|---|---|---|---|---|---|
| Rochester et al. 2009 | Acute verbal cueing + walking intervals | 1 session only | 1 | 1 session | ~1 | NR | No progression |
| Ciro et al. 2013 | STOMP (skill building through task orientated motor practice) | 5 | 120–180 | 2 | 600–900 | NR | Increasing complexity of task as appropriate |
| Tabak et al 2013 | Stationary cycling | 3 | 40 | 8 | 120 | 50%-75% Heart rate max | 5% increase (% heart rate max) in intensity/week |
| Dawley, 2014 | LVST BIG (Lee Silverman voice treatment—Big) Intervention | 0.66 | 55 | 12 | 36.6 | NR | Increase in velocity and movement complexity as appropriate |
| Telenius et al 2015 | High intensity functional exercises (exercise group), Light activity (control group) | 2 | 50–60 | 12 | 100–120 | 12RM load | Increase to maintain 12RM intensity |
A Average of 8 sessions over 3 months,
B Accumulated estimate of stimulus duration for trials, 12RM = 12 repetition maximum; the maximum amount of weight that can be lifted 12 times only